Video Latest - ecancer

Editor's ESMO 2016 roundup

Prof Gordon McVie - Editor in Chief, ecancer

24 Oct 2016

CDK4/6 inhibitors for metastatic breast cancer

Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

14 Oct 2016

ESMO 2016 conference highlights

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

12 Oct 2016

Lurbinectedin in PARP resistant breast cancer

Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

10 Oct 2016

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate

Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA

10 Oct 2016

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair

10 Oct 2016

Custirsen shows no survival benefit in metastatic prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

10 Oct 2016

Negative trial results of custirsen for metastatic prostate cancer

Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France

10 Oct 2016

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland

9 Oct 2016

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

9 Oct 2016

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

9 Oct 2016

Phase I results of a novel FGFR inhibitor

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

9 Oct 2016

Video